Literature DB >> 11133094

Inhibition of Escherichia coli glucosamine synthetase by novel electrophilic analogues of glutamine--comparison with 6-diazo-5-oxo-norleucine.

B Walker1, M F Brown, J F Lynas, S L Martin, A McDowell, B Badet, A J Hill.   

Abstract

A series of electrophilic glutamine analogues based on 6-diazo-5-oxo-norleucine has been prepared, using novel synthetic routes, and evaluated as inhibitors of Escherichia coli glucosamine synthetase. The gamma-dimethylsulphonium salt analogue of glutamine was found to be one of the most potent inactivators of this enzyme yet reported, with an apparent second order rate constant (k2/Ki) of 3.5 x 10(5) M(-1) min(-1).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11133094     DOI: 10.1016/s0960-894x(00)00565-5

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry.

Authors:  Jesse Alt; Michelle C Potter; Camilo Rojas; Barbara S Slusher
Journal:  Anal Biochem       Date:  2015-01-10       Impact factor: 3.365

2.  GFAT2 mediates cardiac hypertrophy through HBP-O-GlcNAcylation-Akt pathway.

Authors:  Akihito Ishikita; Shouji Matsushima; Soichiro Ikeda; Kosuke Okabe; Ryohei Nishimura; Tomonori Tadokoro; Nobuyuki Enzan; Taishi Yamamoto; Masashi Sada; Yoshitomo Tsutsui; Ryo Miyake; Masataka Ikeda; Tomomi Ide; Shintaro Kinugawa; Hiroyuki Tsutsui
Journal:  iScience       Date:  2021-11-26

3.  Inhibitors of glucosamine-6-phosphate synthase as potential antimicrobials or antidiabetics - synthesis and properties.

Authors:  Joanna Stefaniak; Michał G Nowak; Marek Wojciechowski; Sławomir Milewski; Andrzej S Skwarecki
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 4.  We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine.

Authors:  Kathryn M Lemberg; James J Vornov; Rana Rais; Barbara S Slusher
Journal:  Mol Cancer Ther       Date:  2018-09       Impact factor: 6.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.